Literature DB >> 22902597

C-terminal FGF23 is a strong predictor of survival in systolic heart failure.

Damien Gruson1, Thibault Lepoutre, Jean-Marie Ketelslegers, Jean Cumps, Sylvie A Ahn, Michel F Rousseau.   

Abstract

Fibroblast growth factor 23 (FGF23) is a bone-derived hormone involved in the regulation of phosphate and calcium metabolism. We have evaluated the levels of C-terminal FGF23 (Ct-FGF23) in 73 patients presenting heart failure with reduced ejection fraction (HF-REF) and assess their potential predictive value for long-term survival through a 6 years follow-up. Ct-FGF23 levels were markedly increased in HF-REF. In univariate proportional hazard model, survival was related to glomerular filtration rate (eGFR), intact parathyroid hormone (PTH), B-type natriuretic peptides (BNP) and Ct-FGF23. In a multivariate analysis including age, EF, PTH, BNP, Ct-FGF23, calcium, phosphorus and eGFR levels, Ct-FGF23 is the strongest predictor of long term CV death.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22902597     DOI: 10.1016/j.peptides.2012.08.003

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  22 in total

1.  Fibroblast growth factor 23 and heart failure: the plot thickens.

Authors:  Orlando M Gutiérrez
Journal:  Nephrol Dial Transplant       Date:  2015-11-27       Impact factor: 5.992

Review 2.  Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.

Authors:  Julia J Scialla; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2014-04-01       Impact factor: 28.314

3.  Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure.

Authors:  Tamara Isakova; Jessica Houston; Laura Santacruz; Eva Schiavenato; Gabriel Somarriba; William G Harmon; Steven E Lipshultz; Tracie L Miller; Paolo G Rusconi
Journal:  Pediatr Nephrol       Date:  2013-06-06       Impact factor: 3.714

Review 4.  Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators.

Authors:  Alessia Buglioni; John C Burnett
Journal:  Clin Chim Acta       Date:  2014-10-23       Impact factor: 3.786

5.  FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.

Authors:  Chad D Touchberry; Troy M Green; Vladimir Tchikrizov; Jaimee E Mannix; Tiffany F Mao; Brandon W Carney; Magdy Girgis; Robert J Vincent; Lori A Wetmore; Buddhadeb Dawn; Lynda F Bonewald; Jason R Stubbs; Michael J Wacker
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-02-26       Impact factor: 4.310

6.  FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock.

Authors:  Janine Pöss; Felix Mahfoud; Sarah Seiler; Gunnar H Heine; Danilo Fliser; Michael Böhm; Andreas Link
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-09

7.  Calcium, phosphate and calcium phosphate product are markers of outcome in patients with chronic heart failure.

Authors:  Richard M Cubbon; Ceri Haf Thomas; Michael Drozd; John Gierula; Haqeel A Jamil; Rowenna Byrom; Julian H Barth; Mark T Kearney; Klaus K A Witte
Journal:  J Nephrol       Date:  2014-03-11       Impact factor: 3.902

8.  Plasma fibroblast growth factor 23 concentration is increased and predicts mortality in patients on the liver-transplant waiting list.

Authors:  Dominique Prié; Anne Forand; Claire Francoz; Caroline Elie; Isabelle Cohen; Marie Courbebaisse; Dominique Eladari; Didier Lebrec; François Durand; Gerard Friedlander
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

9.  Propensity for Calcification in Serum Associates With 2-Year Cardiovascular Mortality in Ischemic Heart Failure With Reduced Ejection Fraction.

Authors:  Marija Bojic; Lorenz Koller; Daniel Cejka; Alexander Niessner; Bernhard Bielesz
Journal:  Front Med (Lausanne)       Date:  2021-06-18

10.  High FGF23 Levels Failed to Predict Cardiac Hypertrophy in Animal Models of Hyperphosphatemia and Chronic Renal Failure.

Authors:  Ian Moench; Karpagam Aravindhan; Joanne Kuziw; Christine G Schnackenberg; Robert N Willette; John R Toomey; Gregory J Gatto
Journal:  J Endocr Soc       Date:  2021-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.